Long­time In­ter­cept CEO Mark Pruzan­s­ki de­parts as ail­ing NASH com­pa­ny tries to find its fu­ture

Mark Pruzan­s­ki, the CEO who turned “NASH” in­to a house­hold name around biotech, guid­ed his com­pa­ny to the precipice of a nascent field and then watched it fal­ter in the wake of a CRL, will step down on Jan­u­ary.

In­ter­cept Phar­ma­ceu­ti­cals an­nounced Tues­day that Pruzan­s­ki, who has led the biotech since its found­ing, will be re­placed by Jerome Dur­so, a long­time Sanofi ex­ec­u­tive and the COO of In­ter­cept since 2017. Dur­so will take the reins of a com­pa­ny fac­ing a dif­fi­cult road for­ward, as the com­pa­ny tries to con­vince the FDA to re­think its de­ci­sion to re­ject their lead drug for NASH, cut­ting the stock and forc­ing lay­offs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER